Screener
Disc Medicine IRON Other Research — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Disc Medicine in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Disc Medicine’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:33 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205192
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Bitopertin program external expense | $(9,340) | $(8,435) |
| DISC-0974 program external expense | (8,109) | (6,121) |
| DISC-3405 program external expense | (9,187) | (1,668) |
| Other external research and development expense | (2,165) | (1,832) |
| Internal and other research and development expense | (11,312) | (6,748) |
| Commercial expense | $(8,434) | $(1,921) |
| General and administrative expense | $(9,031) | $(6,858) |
| Stock-based compensation expense | $(11,946) | $(6,363) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Disc Medicine's other research — research and development expense?
- Disc Medicine (IRON) reported other research — research and development expense of $2.17M in Q1 2026.
- How has Disc Medicine's other research — research and development expense changed year-over-year?
- Disc Medicine's other research — research and development expense increased by 18.2% year-over-year, from $1.83M to $2.17M.
- What is the long-term trend for Disc Medicine's other research — research and development expense?
- Over 2 years (2023 to 2025), Disc Medicine's other research — research and development expense has grown at a 69.2% compound annual growth rate (CAGR), from $4.75M to $13.6M.
- What does other research — research and development expense mean?
- This metric represents the aggregate costs incurred by the company specifically for research and development activities within the 'Other Research' business segment. It captures expenditures related to early-stage discovery, preclinical studies, and exploratory programs that fall outside of the company's primary clinical-stage product pipeline. Monitoring this expense provides insight into the company's investment in long-term innovation and the diversification of its therapeutic research portfolio.
Ask your AI about Disc Medicine's other research — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude